358 related articles for article (PubMed ID: 17893907)
1. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer.
Sommers BD; Beard CJ; D'Amico AV; Dahl D; Kaplan I; Richie JP; Zeckhauser RJ
Cancer; 2007 Nov; 110(10):2210-7. PubMed ID: 17893907
[TBL] [Abstract][Full Text] [Related]
2. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.
Shimizu F; Igarashi A; Fukuda T; Kawachi Y; Minowada S; Ohashi Y; Fujime M
Jpn J Clin Oncol; 2007 Oct; 37(10):763-74. PubMed ID: 17956899
[TBL] [Abstract][Full Text] [Related]
3. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening.
Yan Y; Carvalhal GF; Catalona WJ; Young JD
Cancer; 2000 Mar; 88(5):1122-30. PubMed ID: 10699903
[TBL] [Abstract][Full Text] [Related]
4. Do older men benefit from curative therapy of localized prostate cancer?
Alibhai SM; Naglie G; Nam R; Trachtenberg J; Krahn MD
J Clin Oncol; 2003 Sep; 21(17):3318-27. PubMed ID: 12947068
[TBL] [Abstract][Full Text] [Related]
5. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
6. [Treatment strategy of localized prostate cancer].
Maeda O
Gan To Kagaku Ryoho; 2003 Jan; 30(1):26-31. PubMed ID: 12557701
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of localized prostatic cancer--different alternatives. Patients with localized prostatic cancer must actively participate in the choice of therapy].
Adolfsson J
Lakartidningen; 2000 Sep; 97(36):3870-4. PubMed ID: 11036336
[TBL] [Abstract][Full Text] [Related]
8. Conventional treatments of localized prostate cancer.
Zerbib M; Zelefsky MJ; Higano CS; Carroll PR
Urology; 2008 Dec; 72(6 Suppl):S25-35. PubMed ID: 19095125
[TBL] [Abstract][Full Text] [Related]
9. A decision support model for cost-effectiveness of radical prostatectomy in localized prostate cancer.
Lyth J; Andersson SO; Andrén O; Johansson JE; Carlsson P; Shahsavar N
Scand J Urol Nephrol; 2012 Feb; 46(1):19-25. PubMed ID: 21905981
[TBL] [Abstract][Full Text] [Related]
10. Treatment decision-making strategies and influences in patients with localized prostate carcinoma.
Gwede CK; Pow-Sang J; Seigne J; Heysek R; Helal M; Shade K; Cantor A; Jacobsen PB
Cancer; 2005 Oct; 104(7):1381-90. PubMed ID: 16080181
[TBL] [Abstract][Full Text] [Related]
11. Value of information on preference heterogeneity and individualized care.
Basu A; Meltzer D
Med Decis Making; 2007; 27(2):112-27. PubMed ID: 17409362
[TBL] [Abstract][Full Text] [Related]
12. Patient treatment preferences in localized prostate carcinoma: The influence of emotion, misconception, and anecdote.
Denberg TD; Melhado TV; Steiner JF
Cancer; 2006 Aug; 107(3):620-30. PubMed ID: 16802287
[TBL] [Abstract][Full Text] [Related]
13. Comparing a generic and individualized information decision support intervention for men newly diagnosed with localized prostate cancer.
Davison BJ; Goldenberg SL; Wiens KP; Gleave ME
Cancer Nurs; 2007; 30(5):E7-15. PubMed ID: 17876177
[TBL] [Abstract][Full Text] [Related]
14. Preference assessment method affects decision-analytic recommendations: a prostate cancer treatment example.
Elkin EB; Cowen ME; Cahill D; Steffel M; Kattan MW
Med Decis Making; 2004; 24(5):504-10. PubMed ID: 15358999
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer screening: a decision analysis.
Cantor SB; Spann SJ; Volk RJ; Cardenas MP; Warren MM
J Fam Pract; 1995 Jul; 41(1):33-41. PubMed ID: 7798064
[TBL] [Abstract][Full Text] [Related]
16. [Competitive morbidity ant its impact on life expectancy: evaluation and inclusion in the therapeutic decision regarding localized prostatic cancer].
Soulié M; Villers A; Richaud P; Prapotnich D; Ruffion A; Grosclaude P
Prog Urol; 2001 Dec; 11(6):1195-204. PubMed ID: 11859652
[TBL] [Abstract][Full Text] [Related]
17. The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis.
Mold JW; Holtgrave DR; Bisonni RS; Marley DS; Wright RA; Spann SJ
J Fam Pract; 1992 May; 34(5):561-8. PubMed ID: 1578205
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer Tx. Therapeutic options based on tumor grade, life expectancy, and patient preferences.
Cohen SP; Jaskulsky SR
Geriatrics; 2001 Feb; 56(2):39, 42, 47-8 passim. PubMed ID: 11219024
[TBL] [Abstract][Full Text] [Related]
19. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.
Howard K; Barratt A; Mann GJ; Patel MI
Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680
[TBL] [Abstract][Full Text] [Related]
20. Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE.
Marr PL; Elkin EP; Arredondo SA; Broering JM; DuChane J; Carroll PR
J Urol; 2006 Apr; 175(4):1326-31. PubMed ID: 16515991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
